[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @andrewcaravello Andrew Caravello, DO Andrew Caravello, DO posts on X about $ibrx, $nwbo, science, future the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::244291506/interactions)  - X Week XXXXXX -XX% - X Month XXXXXXX -XXXX% - X Months XXXXXXX -XX% - X Year XXXXXXXXX +3,189% ### Mentions: XX [#](/creator/twitter::244291506/posts_active)  - X Week XX -XX% - X Month XXX +28% - X Months XXX +391% - X Year XXX +1,550% ### Followers: XXXXX [#](/creator/twitter::244291506/followers)  - X Week XXXXX +2.30% - X Month XXXXX +9.20% - X Months XXXXX +64% - X Year XXXXX +176% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::244291506/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) XXXX% [stocks](/list/stocks) XXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [social networks](/list/social-networks) XXXX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [$ibrx](/topic/$ibrx) #5, [$nwbo](/topic/$nwbo) #7, [science](/topic/science) 8.7%, [future](/topic/future) 4.35%, [rescue](/topic/rescue) 4.35%, [$aim](/topic/$aim) 4.35%, [$pfe](/topic/$pfe) 4.35%, [$mrk](/topic/$mrk) 4.35%, [$bmy](/topic/$bmy) 4.35%, [$tech](/topic/$tech) #2 **Top accounts mentioned or mentioned by** [@cfiedle24879045](/creator/undefined) [@maveric92283613](/creator/undefined) [@hoffmann6383](/creator/undefined) [@dcvaxdefender](/creator/undefined) [@smyley4evr1](/creator/undefined) [@jacobyorkndxt](/creator/undefined) [@nocontextbrits](/creator/undefined) [@ustraderep](/creator/undefined) [@commercegov](/creator/undefined) [@potuss](/creator/undefined) [@drpatsoonshiong](/creator/undefined) [@fda](/creator/undefined) [@nature](/creator/undefined) [@ivanbamartin](/creator/undefined) [@andrshidalgo16](/creator/undefined) [@lai9uan](/creator/undefined) [@danielacerezo](/creator/undefined) [@yale](/creator/undefined) [@usfda](/creator/undefined) [@seckennedy](/creator/undefined) **Top assets mentioned** [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) [Pfizer, Inc. (PFE)](/topic/$pfe) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [BIO-TECHNE Corp (TECH)](/topic/$tech) [Danaher Corporation (DHR)](/topic/$dhr) [Polymesh (POLYX)](/topic/polymesh) ### Top Social Posts Top posts by engagements in the last XX hours "🧬 The Convergence Architecture: How ImmunityBios $IBRX #Anktiva Is Being Measured Against the #DCVax Instructional Platform at the Center of $NWBO Technology 💡 TLDR The National Cancer Institutes QUILT-502 trial in HER2-positive recurrent or metastatic endometrial cancer is testing four coordinated immune components: a HER2-targeted dendritic-cell vaccine (AdHER2DC) pembrolizumab (Mercks antiPD-1) lenvatinib (Eisais VEGFR/FGFR inhibitor) andonly in one armthe IL-15 superagonist N-803 (Anktiva) from ImmunityBio. QUILT-502 is a Phase I/II study with the Phase II portion designed to evaluate" [X Link](https://x.com/andrewcaravello/status/1998155639789678703) 2025-12-08T22:20Z 1448 followers, 4359 engagements "🧬 #FDA Just Revealed the Exact Pathway $NWBO #DCVax-L Needs The new FDA Grand Rounds isnt about DCVax but it is about the regulatory engine DCVax-L runs on. On December XX the Agency is dedicating an entire session to Real-World Evidence (RWE)how to validate it how to judge external controls and how to use it in oncology approvals when traditional RCTs are impossible. That matters because DCVax-Ls Phase X trial used: an external control arm a crossover-contaminated dataset and survival outcomes proven through RWE-strength comparisons The invited speaker Dr. Marie Bradley is the FDAs senior" [X Link](https://x.com/andrewcaravello/status/1996015113673797986) 2025-12-03T00:34Z 1448 followers, 9974 engagements "The Case Against $IBRX #Anktiva: How an IL XX Superagonist Became a Biological Placebo in Value Terms When Anktiva N XXX first appeared on slides and conference stages it sounded like the missing piece of modern oncology. An IL XX superagonist that could awaken exhausted immune cells. Expand natural killer cells and CD8 T cells. Rescue patients whose immune systems had been beaten down by chemo radiation and prior therapies. Plug the energy leak in immunotherapy and turn modest checkpoint responses into durable cures. On paper that is a lovely story. But drugs do not get to live on paper." [X Link](https://x.com/andrewcaravello/status/1996584962917544146) 2025-12-04T14:18Z 1448 followers, 3493 engagements "The slide looks impressive until you compare it to what modern BCG rescue already accomplishes in papillary NMIBC. $IBRX #Anktiva plus BCG did not demonstrate the strongest anything in papillary disease; it showed the opposite. When the data were matched against contemporary BCG re-induction cohorts the combination produced a statistically significant worsening in recurrence-free survival with a hazard ratio of XXXX and a p value of XXXXX. The bladder-preservation number being advertised is also misleading because papillary NMIBC already preserves the bladder in ninety five to ninety seven" [X Link](https://x.com/andrewcaravello/status/1996592799723008277) 2025-12-04T14:49Z 1448 followers, XXX engagements "@CFiedle24879045 Haha or check out a company thats actually curing cancer. $NWBO #DCVax has peer-reviewed survival data validated across academic centers all over the world" [X Link](https://x.com/andrewcaravello/status/1996641491083841737) 2025-12-04T18:03Z 1447 followers, XXX engagements "Single-arm approvals have been around for decades in low-mortality settings like BCG-unresponsive NMIBC where BCG already works well for many patients. That is why $IBRX #Anktiva got a narrow CIS label but failed in papillary disease once modern BCG outcomes were considered. And the new FDA framework including the Plausible Mechanism Pathway does not strengthen Anktivas case at all. That pathway requires showing a mechanism that produces a clear independent clinical effect. Anktiva never separated its effect from BCG and in papillary disease the combination actually performed worse than BCG" [X Link](https://x.com/andrewcaravello/status/1996652558065221861) 2025-12-04T18:47Z 1448 followers, XXX engagements "That #GBM claim for $IBRX is based on a tiny single-arm study using disease control which in #glioblastoma often reflects imaging artifacts rather than drug effect. Nothing in that dataset shows independent activity. If youre looking for an immunotherapy that has actually shifted survival #DCVax-L is the only one with phase X peer-reviewed multi-center evidence across multiple countries. The validated GBM signal in this space belongs to NWBO not IBRX" [X Link](https://x.com/andrewcaravello/status/1996663973203030402) 2025-12-04T19:32Z 1448 followers, XXX engagements "You can probably understand why I react the way I do when $IBRX #Anktiva gets framed as some kind of breakthrough. It has failed in every solid tumor setting tested and in bladder cancer it hasnt shown any independent activity beyond what BCG already achieves. In papillary disease the combination actually performed worse than modern BCG re-induction. When you look at it through that lens and when you factor in my own experience watching someone close to me do exactly what the BCG data say many patients can do its not hard to see why this strikes a nerve. Anyone who has been through it with" [X Link](https://x.com/andrewcaravello/status/1996778618064707614) 2025-12-05T03:08Z 1448 followers, XXX engagements "🧱 Tokenizing Trust: Why $NWBO Should Build On Polymesh for Investor Protection Market Integrity IP Security and Long-Term Capital Access TLDR Tokenization is no longer a fringe idea or a crypto experiment. It is becoming a mainstream modernization of traditional market infrastructure but only when executed within the full regulatory framework that governs U S securities. SIFMA the primary policy voice of broker-dealers investment banks custodians and clearing firms has stated openly that tokenized markets must operate with the same investor protections surveillance transparency and lifecycle" [X Link](https://x.com/andrewcaravello/status/1998907262094442644) 2025-12-11T00:06Z 1448 followers, 1341 engagements "If pointing out the evidence counts as nothing better to do that says more about the bullish case than anything Ive written. The truth is simple: once you separate N-803 from the BCG backbone $IBRX #Anktiva behaves like a placebo. And in papillary disease it was even clearer patients on Anktiva + BCG actually did worse than patients who just received modern BCG re-induction. The recurrence rate was higher the hazard ratio favored BCG alone and thats exactly why the FDA rejected the papillary indication. So if the drug cant show independent benefit in CIS and actually worsens outcomes in" [X Link](https://x.com/andrewcaravello/status/1996751268467892556) 2025-12-05T01:19Z 1441 followers, XXX engagements "🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System PART X of X DCVax-T #Eden SI XX And The Strategic Moats Around The Immune Operating System Part X followed the biology from end to end: how CKM hijacks NF kB in tumors how DC1 is manufactured through the GM-CSF and IL X corridor how NK-receptor logic gates emerge how epitope spreading turns a static vaccine into self-updating software and how CXCR3 routing determines whether PD X can work at all. Part X picks up where that leaves off and asks a different question: given this instructional engine how do you" [X Link](https://x.com/andrewcaravello/status/1998720935835086866) 2025-12-10T11:46Z 1441 followers, XX engagements "Cant disagree with that 😅 Its a good thing LP chose the UK for first approval. The MHRA has already built the framework for RWE driven tissue agnostic immunotherapies and DCVax fits that model better than anything in big pharmas pipeline. The move protected the science and positions NWBO to come back to the FDA from a position of strength" [X Link](https://x.com/andrewcaravello/status/1996948563662692689) 2025-12-05T14:23Z 1448 followers, XX engagements "THE $NWBO #DCVax HIDDEN ARCHITECTURE Part II of II The Factory The Federation and the Immune Operating System By the time Northwest Biotherapeutics secured commercial rights to the DC1 method the company owned the instructions for the immune system but not yet the factory capable of executing them at scale. Intellectual property can give you the blueprint for a cathedral; it cannot stack a single stone. Manufacturing is the stonework of cell therapy the part of the enterprise that cannot be faked or outsourced indefinitely. NWBO understood this years before the market did. That is why Advent" [X Link](https://x.com/andrewcaravello/status/1997424985703678229) 2025-12-06T21:56Z 1447 followers, 1412 engagements "This argument collapses both scientifically and regulatorily. Epogen and Neupogen are supportive hematologic therapies because they replace or stimulate a specific blood lineage in a predictable way. They do not rely on tumor biology and they do not alter the immune environment outside the targeted lineage. $IBRX #Anktiva does none of this. It is not a lineage support drug. It is an IL fifteen superagonist that pushes NK and T cells into global cytokine activation without correcting the underlying cause of lymphopenia and without any evidence that raising absolute lymphocyte count changes" [X Link](https://x.com/andrewcaravello/status/1997514134343016800) 2025-12-07T03:50Z 1447 followers, 1153 engagements "🔬The Two Cytokines at the Gate: How $IBRX #Anktiva and $NWBO #DCVax Expose the Future Architecture of Cancer Immunity TLDR A 2025 immunology paper on IL-15armored NK and CAR-NK therapies revealed a single phenomenon across every model: early tumor regression followed by uncontrolled immune expansion organ infiltration and premature host death independent of CAR targeting tumor type NK source or dose. IL-15 produces force without structure. IL-7 produces structure without collapse. Clinically $IBRX #Anktiva avoids IL-15s catastrophic biology only by weakening IL-15s potency which is why it" [X Link](https://x.com/andrewcaravello/status/1997829905229259180) 2025-12-08T00:45Z 1444 followers, 8033 engagements "🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System $AIM $PFE $MRK $BMY $TECH $DHR $IBRX $ESALY PART X of X DCVax-T #Eden SI XX And The Strategic Moats Around The Immune Operating System Part X followed the biology from end to end: how CKM hijacks NF kB in tumors how DC1 is manufactured through the GM-CSF and IL X corridor how NK-receptor logic gates emerge how epitope spreading turns a static vaccine into self-updating software and how CXCR3 routing determines whether PD X can work at all. Part X picks up where that leaves off and asks a different question: given" [X Link](https://x.com/andrewcaravello/status/1998721396357173720) 2025-12-10T11:48Z 1444 followers, XXX engagements "🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System $AIM $PFE $MRK $BMY $TECH $DHR $IBRX $ESALY PART X OF X TLDR CKM = Chemokine-Modulatory Regimen: Rintatolimod (Ampligen) + Interferon- + a COX-2 inhibitor (usually celecoxib). This three-part regimen selectively boosts CXCL9/10 in NF-Bhigh tumor tissue while avoiding activation in healthy tissue creating a tumor-specific immune switch that turns cold tumors hot. X. CKM is a tumor-selective immune amplifier not a blunt stimulant. In early TNBC (NCT04081389) CKM + paclitaxel produced large CD8 influx high CXCL9/10" [X Link](https://x.com/andrewcaravello/status/1998721893013053768) 2025-12-10T11:50Z 1444 followers, 3765 engagements "📘 VOLUME I THE ARCHITECTURE OF $NWBO #DCVax IMMUNITY Part Two of Two Dendritic Cell Therapies and Modulation of Endogenous DC to Overcome I O via @YouTube How the Antigen Constellation Boolean Logic In Situ Vaccination and CKM Close the Loop of the Immune Operating System SECTION X The Antigen Constellation If the Chemokine Compass determines where immune cells go the Antigen Constellation determines what they see when they arrive. Here Kalinski exposes the core flaw in most targeted immunotherapies for solid tumors. Tumors do not present a single antigen. They present shifting" [X Link](https://x.com/andrewcaravello/status/1998913141850112282) 2025-12-11T00:30Z 1447 followers, 2106 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@andrewcaravello Andrew Caravello, DO
Andrew Caravello, DO posts on X about $ibrx, $nwbo, science, future the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX -XX%
- X Month XXXXXXX -XXXX%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX +3,189%
Mentions: XX #
- X Week XX -XX%
- X Month XXX +28%
- X Months XXX +391%
- X Year XXX +1,550%
Followers: XXXXX #
- X Week XXXXX +2.30%
- X Month XXXXX +9.20%
- X Months XXXXX +64%
- X Year XXXXX +176%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence finance XXXX% stocks XXXX% cryptocurrencies XXXX% social networks XXXX% technology brands XXXX%
Social topic influence $ibrx #5, $nwbo #7, science 8.7%, future 4.35%, rescue 4.35%, $aim 4.35%, $pfe 4.35%, $mrk 4.35%, $bmy 4.35%, $tech #2
Top accounts mentioned or mentioned by @cfiedle24879045 @maveric92283613 @hoffmann6383 @dcvaxdefender @smyley4evr1 @jacobyorkndxt @nocontextbrits @ustraderep @commercegov @potuss @drpatsoonshiong @fda @nature @ivanbamartin @andrshidalgo16 @lai9uan @danielacerezo @yale @usfda @seckennedy
Top assets mentioned ImmunityBio, Inc. Common Stock (IBRX) Pfizer, Inc. (PFE) Merck & Co., Inc. (MRK) Bristol-Myers Squibb Co (BMY) BIO-TECHNE Corp (TECH) Danaher Corporation (DHR) Polymesh (POLYX)
Top Social Posts
Top posts by engagements in the last XX hours
"🧬 The Convergence Architecture: How ImmunityBios $IBRX #Anktiva Is Being Measured Against the #DCVax Instructional Platform at the Center of $NWBO Technology 💡 TLDR The National Cancer Institutes QUILT-502 trial in HER2-positive recurrent or metastatic endometrial cancer is testing four coordinated immune components: a HER2-targeted dendritic-cell vaccine (AdHER2DC) pembrolizumab (Mercks antiPD-1) lenvatinib (Eisais VEGFR/FGFR inhibitor) andonly in one armthe IL-15 superagonist N-803 (Anktiva) from ImmunityBio. QUILT-502 is a Phase I/II study with the Phase II portion designed to evaluate"
X Link 2025-12-08T22:20Z 1448 followers, 4359 engagements
"🧬 #FDA Just Revealed the Exact Pathway $NWBO #DCVax-L Needs The new FDA Grand Rounds isnt about DCVax but it is about the regulatory engine DCVax-L runs on. On December XX the Agency is dedicating an entire session to Real-World Evidence (RWE)how to validate it how to judge external controls and how to use it in oncology approvals when traditional RCTs are impossible. That matters because DCVax-Ls Phase X trial used: an external control arm a crossover-contaminated dataset and survival outcomes proven through RWE-strength comparisons The invited speaker Dr. Marie Bradley is the FDAs senior"
X Link 2025-12-03T00:34Z 1448 followers, 9974 engagements
"The Case Against $IBRX #Anktiva: How an IL XX Superagonist Became a Biological Placebo in Value Terms When Anktiva N XXX first appeared on slides and conference stages it sounded like the missing piece of modern oncology. An IL XX superagonist that could awaken exhausted immune cells. Expand natural killer cells and CD8 T cells. Rescue patients whose immune systems had been beaten down by chemo radiation and prior therapies. Plug the energy leak in immunotherapy and turn modest checkpoint responses into durable cures. On paper that is a lovely story. But drugs do not get to live on paper."
X Link 2025-12-04T14:18Z 1448 followers, 3493 engagements
"The slide looks impressive until you compare it to what modern BCG rescue already accomplishes in papillary NMIBC. $IBRX #Anktiva plus BCG did not demonstrate the strongest anything in papillary disease; it showed the opposite. When the data were matched against contemporary BCG re-induction cohorts the combination produced a statistically significant worsening in recurrence-free survival with a hazard ratio of XXXX and a p value of XXXXX. The bladder-preservation number being advertised is also misleading because papillary NMIBC already preserves the bladder in ninety five to ninety seven"
X Link 2025-12-04T14:49Z 1448 followers, XXX engagements
"@CFiedle24879045 Haha or check out a company thats actually curing cancer. $NWBO #DCVax has peer-reviewed survival data validated across academic centers all over the world"
X Link 2025-12-04T18:03Z 1447 followers, XXX engagements
"Single-arm approvals have been around for decades in low-mortality settings like BCG-unresponsive NMIBC where BCG already works well for many patients. That is why $IBRX #Anktiva got a narrow CIS label but failed in papillary disease once modern BCG outcomes were considered. And the new FDA framework including the Plausible Mechanism Pathway does not strengthen Anktivas case at all. That pathway requires showing a mechanism that produces a clear independent clinical effect. Anktiva never separated its effect from BCG and in papillary disease the combination actually performed worse than BCG"
X Link 2025-12-04T18:47Z 1448 followers, XXX engagements
"That #GBM claim for $IBRX is based on a tiny single-arm study using disease control which in #glioblastoma often reflects imaging artifacts rather than drug effect. Nothing in that dataset shows independent activity. If youre looking for an immunotherapy that has actually shifted survival #DCVax-L is the only one with phase X peer-reviewed multi-center evidence across multiple countries. The validated GBM signal in this space belongs to NWBO not IBRX"
X Link 2025-12-04T19:32Z 1448 followers, XXX engagements
"You can probably understand why I react the way I do when $IBRX #Anktiva gets framed as some kind of breakthrough. It has failed in every solid tumor setting tested and in bladder cancer it hasnt shown any independent activity beyond what BCG already achieves. In papillary disease the combination actually performed worse than modern BCG re-induction. When you look at it through that lens and when you factor in my own experience watching someone close to me do exactly what the BCG data say many patients can do its not hard to see why this strikes a nerve. Anyone who has been through it with"
X Link 2025-12-05T03:08Z 1448 followers, XXX engagements
"🧱 Tokenizing Trust: Why $NWBO Should Build On Polymesh for Investor Protection Market Integrity IP Security and Long-Term Capital Access TLDR Tokenization is no longer a fringe idea or a crypto experiment. It is becoming a mainstream modernization of traditional market infrastructure but only when executed within the full regulatory framework that governs U S securities. SIFMA the primary policy voice of broker-dealers investment banks custodians and clearing firms has stated openly that tokenized markets must operate with the same investor protections surveillance transparency and lifecycle"
X Link 2025-12-11T00:06Z 1448 followers, 1341 engagements
"If pointing out the evidence counts as nothing better to do that says more about the bullish case than anything Ive written. The truth is simple: once you separate N-803 from the BCG backbone $IBRX #Anktiva behaves like a placebo. And in papillary disease it was even clearer patients on Anktiva + BCG actually did worse than patients who just received modern BCG re-induction. The recurrence rate was higher the hazard ratio favored BCG alone and thats exactly why the FDA rejected the papillary indication. So if the drug cant show independent benefit in CIS and actually worsens outcomes in"
X Link 2025-12-05T01:19Z 1441 followers, XXX engagements
"🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System PART X of X DCVax-T #Eden SI XX And The Strategic Moats Around The Immune Operating System Part X followed the biology from end to end: how CKM hijacks NF kB in tumors how DC1 is manufactured through the GM-CSF and IL X corridor how NK-receptor logic gates emerge how epitope spreading turns a static vaccine into self-updating software and how CXCR3 routing determines whether PD X can work at all. Part X picks up where that leaves off and asks a different question: given this instructional engine how do you"
X Link 2025-12-10T11:46Z 1441 followers, XX engagements
"Cant disagree with that 😅 Its a good thing LP chose the UK for first approval. The MHRA has already built the framework for RWE driven tissue agnostic immunotherapies and DCVax fits that model better than anything in big pharmas pipeline. The move protected the science and positions NWBO to come back to the FDA from a position of strength"
X Link 2025-12-05T14:23Z 1448 followers, XX engagements
"THE $NWBO #DCVax HIDDEN ARCHITECTURE Part II of II The Factory The Federation and the Immune Operating System By the time Northwest Biotherapeutics secured commercial rights to the DC1 method the company owned the instructions for the immune system but not yet the factory capable of executing them at scale. Intellectual property can give you the blueprint for a cathedral; it cannot stack a single stone. Manufacturing is the stonework of cell therapy the part of the enterprise that cannot be faked or outsourced indefinitely. NWBO understood this years before the market did. That is why Advent"
X Link 2025-12-06T21:56Z 1447 followers, 1412 engagements
"This argument collapses both scientifically and regulatorily. Epogen and Neupogen are supportive hematologic therapies because they replace or stimulate a specific blood lineage in a predictable way. They do not rely on tumor biology and they do not alter the immune environment outside the targeted lineage. $IBRX #Anktiva does none of this. It is not a lineage support drug. It is an IL fifteen superagonist that pushes NK and T cells into global cytokine activation without correcting the underlying cause of lymphopenia and without any evidence that raising absolute lymphocyte count changes"
X Link 2025-12-07T03:50Z 1447 followers, 1153 engagements
"🔬The Two Cytokines at the Gate: How $IBRX #Anktiva and $NWBO #DCVax Expose the Future Architecture of Cancer Immunity TLDR A 2025 immunology paper on IL-15armored NK and CAR-NK therapies revealed a single phenomenon across every model: early tumor regression followed by uncontrolled immune expansion organ infiltration and premature host death independent of CAR targeting tumor type NK source or dose. IL-15 produces force without structure. IL-7 produces structure without collapse. Clinically $IBRX #Anktiva avoids IL-15s catastrophic biology only by weakening IL-15s potency which is why it"
X Link 2025-12-08T00:45Z 1444 followers, 8033 engagements
"🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System $AIM $PFE $MRK $BMY $TECH $DHR $IBRX $ESALY PART X of X DCVax-T #Eden SI XX And The Strategic Moats Around The Immune Operating System Part X followed the biology from end to end: how CKM hijacks NF kB in tumors how DC1 is manufactured through the GM-CSF and IL X corridor how NK-receptor logic gates emerge how epitope spreading turns a static vaccine into self-updating software and how CXCR3 routing determines whether PD X can work at all. Part X picks up where that leaves off and asks a different question: given"
X Link 2025-12-10T11:48Z 1444 followers, XXX engagements
"🧬 Complete Evidence Map: Kalinskis Science + The $NWBO #DCVax Operating System $AIM $PFE $MRK $BMY $TECH $DHR $IBRX $ESALY PART X OF X TLDR CKM = Chemokine-Modulatory Regimen: Rintatolimod (Ampligen) + Interferon- + a COX-2 inhibitor (usually celecoxib). This three-part regimen selectively boosts CXCL9/10 in NF-Bhigh tumor tissue while avoiding activation in healthy tissue creating a tumor-specific immune switch that turns cold tumors hot. X. CKM is a tumor-selective immune amplifier not a blunt stimulant. In early TNBC (NCT04081389) CKM + paclitaxel produced large CD8 influx high CXCL9/10"
X Link 2025-12-10T11:50Z 1444 followers, 3765 engagements
"📘 VOLUME I THE ARCHITECTURE OF $NWBO #DCVax IMMUNITY Part Two of Two Dendritic Cell Therapies and Modulation of Endogenous DC to Overcome I O via @YouTube How the Antigen Constellation Boolean Logic In Situ Vaccination and CKM Close the Loop of the Immune Operating System SECTION X The Antigen Constellation If the Chemokine Compass determines where immune cells go the Antigen Constellation determines what they see when they arrive. Here Kalinski exposes the core flaw in most targeted immunotherapies for solid tumors. Tumors do not present a single antigen. They present shifting"
X Link 2025-12-11T00:30Z 1447 followers, 2106 engagements